KBC Group NV Raises Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

KBC Group NV raised its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 8.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,096 shares of the biopharmaceutical company’s stock after buying an additional 322 shares during the quarter. KBC Group NV’s holdings in Intra-Cellular Therapies were worth $540,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB grew its holdings in Intra-Cellular Therapies by 124.3% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 133 shares in the last quarter. Accredited Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 4th quarter worth $28,000. Farther Finance Advisors LLC grew its holdings in shares of Intra-Cellular Therapies by 452.5% during the 1st quarter. Farther Finance Advisors LLC now owns 884 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 724 shares during the period. SeaCrest Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 1st quarter worth $251,000. Finally, Advisor Resource Council purchased a new position in shares of Intra-Cellular Therapies during the 1st quarter worth $258,000. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ITCI has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Wall Street Zen initiated coverage on Intra-Cellular Therapies in a report on Thursday, May 15th. They set a “hold” rating for the company. Eleven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $109.70.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $131.87 on Friday. The business has a 50-day moving average of $131.87 and a 200 day moving average of $124.87. Intra-Cellular Therapies, Inc. has a 12 month low of $68.16 and a 12 month high of $131.98. The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.